Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not

Comparisons of survival between dialysis and nondialysis care for older adults with kidney failure have been limited to those managed by nephrologists, and are vulnerable to lead and immortal time biases. So we compared time to all-cause mortality among older adults with kidney failure treated vs. not treated with chronic dialysis. Our retrospective cohort study used linked administrative and laboratory data to identify adults aged 65 or more years of age in Alberta, Canada, with kidney failure (2002-2012), defined by two or more consecutive outpatient estimated glomerular filtration rates less than 10 mL/min/1.73m2, spanning 90 or more days. We used marginal structural Cox models to assess the association between receipt of dialysis and all-cause mortality by allowing control for both time-varying and baseline confounders. Overall, 838 patients met inclusion criteria (mean age 79.1; 48.6% male; mean estimated glomerular filtration rate 7.8 mL/min/1.73m2). Dialysis treatment (vs. no dialysis) was associated with a significantly lower risk of death for the first three years of follow-up (hazard ratio 0.59 [95% confidence interval 0.46-0.77]), but not thereafter (1.22 [0.69-2.17]). However, dialysis was associated with a significantly higher risk of hospitalization (1.40 [1.16-1.69]). Thus, among older adults with kidney failure, treatment with dialysis was associated with longer survival up to three years after reaching kidney failure, though with a higher risk of hospital admissions. These findings may assist shared decision-making about treatment of kidney failure

A Scoping Review of Frailty and Acute Care in Middle-Aged and Older Individuals with Recommendations for Future Research

There is general agreement that frailty is a state of heightened vulnerability to stressors arising from impairments in multiple systems leading to declines in homeostatic reserve and resiliency, but unresolved issues persist about its detection, underlying pathophysiology, and relationship with aging, disability, and multimorbidity. A particularly challenging area is the relationship between frailty and hospitalization. Based on the deliberations of a 2014 Canadian expert consultation meeting and a scoping review of the relevant literature between 2005 and 2015, this discussion paper presents a review of the current state of knowledge on frailty in the acute care setting, including its prevalence and ability to both predict the occurrence and outcomes of hospitalization. The examination of the available evidence highlighted a number of specific clinical and research topics requiring additional study. We conclude with a series of consensus recommendations regarding future research priorities in this important area

靴傷症ノ療法ニ就テ

Table summarizing methods used for assessing primary and secondary outcomes. (DOCX 104 kb

Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation:A Multinational Delphi Survey With Patients, Caregivers, and Health Professionals

Background: Inconsistencies in outcome reporting and frequent omission of patient-centered outcomes can diminish the value of trials in treatment decision-making. We identified critically important outcome domains in kidney transplantation based on the shared priorities of patients/caregivers and health professionals. Methods: In a 3-round Delphi survey, patients/caregivers and health professionals rated the importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and provided comments. During Round 2 and 3, participants re-rated the outcomes after reviewing their own score, the distribution of the respondents’ scores, and comments. We calculated the median, mean, and proportion rating 7-9 (critically important), and analyzed comments thematically. Results: 1018 participants (461 [45%] patients/caregivers and 557 [55%] health professionals) from 79 countries completed Round 1, and 779 (77%) completed Round 3. The top eight outcomes that met the consensus criteria in Round 3 (mean ≥7.5, median ≥8 and proportion >85%) in both groups were graft loss, graft function, chronic rejection, acute rejection, mortality, infection, cancer (excluding skin) and cardiovascular disease. Compared with health professionals, patients/caregivers gave higher priority to six outcomes (mean difference of 0.5 or more): skin cancer, surgical complications, cognition, blood pressure, depression, and ability to work. We identified five themes: capacity to control and inevitability, personal relevance, debilitating repercussions, gaining awareness of risks, and addressing knowledge gaps. Conclusions: Graft complications and severe comorbidities were critically important for both stakeholder groups. These stakeholder-prioritized outcomes will inform the core outcome set to improve the consistency and relevance of trials in kidney transplantation

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Care and Outcomes for Older Adults with Advanced Chronic Kidney Disease

The prevalence of older adults with advanced chronic kidney disease (CKD) is increasing globally, although optimal treatment remains uncertain. We examined in this thesis survival outcomes for older adults with kidney failure treated and not treated with dialysis. We also sought to identify barriers and facilitators to optimal conservative (non-dialysis) care for older adults with kidney failure managed by primary care physicians. We conducted three studies: a population-based retrospective cohort study using administrative and laboratory data to compare survival outcomes between dialysis and non-dialysis treatment; a qualitative descriptive study to explore primary care physician experiences when providing conservative care to older adults with kidney failure; and a cross-sectional population-based survey study within Alberta, Canada, to quantify results from the previous qualitative study. These last two studies formed a sequential exploratory mixed methods program of work to identify barriers and facilitators to community-based conservative care. We found that compared to non-dialysis care, dialysis was associated with a reduced risk of all-cause mortality but only within the first three years following onset of kidney failure. Conservative care for older adults is commonly provided by primary care physicians; however, they face substantial barriers to optimal care. Primary care physicians also expressed a need for resources including telephone access to nephrology or conservative care expertise, better access to conservative care clinics, and improved ability to appropriately co-manage patients with nephrologists. Research in conservative care has previously focused on patients with advanced CKD referred to nephrology. However, conservative care and outcomes among older adults not referred to nephrology is largely unknown. This thesis examined clinical care and outcomes through a wider perspective. To foster clinical impact we worked closely from conceptualization to dissemination stages with key stakeholders in Alberta including the Southern Alberta Conservative Management Program, the Conservative Kidney Management Pathway Steering Committee, the Kidney Health Strategic Clinical Network, and the Alberta College of Family Physicians. Our findings contributed to development of a conservative kidney management clinical care pathway and province-wide telephone access for primary care physicians to directly contact nephrologists and conservative care specialists

A comparative study of dementia-related service provision and configuration in Canada

The purpose of this study was to describe and compare the provision of dementia-related services throughout the disease trajectory. Previously collected interview data from family physicians, geriatric specialists, and case managers in Calgary, Edmonton, and Ottawa (n=34) using a standardized interview schedule were quantified and thematically categorized. The proportions of participants that identified specific services were analyzed at each stage and cumulatively using chi-square tests; proportions of identifiers were also examined through time using time-to-event analysis. Further, relationships between participants and services were described using social network analysis. The following services were analyzed: neuroimaging, depression-related, delirium-related, future planning, informal support, Alzheimer Society and related, in-home support, and day program services. Overall, the findings indicated variation in service delivery among professionals and locations; family physicians and Ottawa clinicians, particularly, may not be providing services at frequencies and times recommended in national guidelines

A Description of Advanced Chronic Kidney Disease Patients in a Major Urban Center Receiving Conservative Care

Background: Conservative/palliative (nondialysis) management is an option for some individuals for treatment of stage 5 chronic kidney disease (CKD). Little is known about these individuals treated with conservative care in the Canadian setting. Objective: To describe the characteristics of patients treated with conservative care for category G5 non-dialysis CKD in a Canadian context. Design: Retrospective chart review. Setting: Urban nephrology center. Patients: Patients with G5 non-dialysis CKD (estimated glomerular filtration rate <15 mL/min/1.73 m 2 ). Measurements: Baseline patient demographic and clinical characteristics of conservative care follow-up, advanced care planning, and death. Methods: We undertook a descriptive analysis of individuals enrolled in a conservative care program between January 1, 2009, and June 30, 2015. Results: One hundred fifty-four patients were enrolled in the conservative care program. The mean age and standard deviation was 81.4 ± 9.0 years. The mean modified Charlson Comorbidity Index score was 3.4 ± 2.8. The median duration of conservative care participation was 11.5 months (interquartile range: 4-25). Six (3.9%) patients changed their modality to dialysis. One hundred three (66.9%) patients died during the study period. Within the deceased cohort, most (88.2%) patients completed at least some advanced care planning before death, and most (81.7%) of them died at their preferred place. Twenty-seven (26.7%) individuals died in hospital. Limitations: Single-center study with biases inherent to a retrospective study. Generalizability to non-Canadian settings may be limited. Conclusions: We found that individuals who chose conservative care were very old and did not have high levels of comorbidity. Few individuals who chose conservative care changed modality and accepted dialysis. The proportions of engagement in advanced care planning and of death in place of choice were high in this population. Death in hospital was uncommon in this population